Exclusive - US FDA launches fresh safety scrutiny of approved RSV therapies for infants

U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective ...
The Manila Times

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed ...

ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...